Telix expects FY2026 revenue and other income above US$1 billion, tracks upper end of guidance range

• Telix expects FY 2026 revenue and other income to exceed US$1 billion, tracking at the upper end of revenue guidance of US$950 million to US$970 million.
• Outlook includes US$40 million in non-refundable other income from Regeneron; FY 2026 R&D spend guidance raised to US$230 million to US$270 million.
• Q2 group revenue totaled US$247 million, up 7% quarter-on-quarter, up 21% year-on-year; Precision Medicine revenue was US$202 million, up 9% QoQ.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.